| Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD) (NCT00229385) | Sheba Medical Center | 2006-01-01 |
| Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging (NCT00288340) | Vanderbilt University | 2006-01-01 |
| Efficacy and Safety of Psychopharmacotherapy in Patients With Schizophrenia or Bipolar Disorders (NCT00330226) | Seoul National University Hospital | 2006-01-01 |
| Disturbances of Kynurenine Pathway of Trytophan Metabolism in Schizophrenia: A Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) Study (NCT00573300) | North Suffolk Mental Health Association | 2006-01-01 |
| Cognitive Remediation Therapy and Schizophrenia (NCT01078129) | Hôpital le Vinatier | 2006-01-01 |
| Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder (NCT00139919) | Solvay Pharmaceuticals | 2006-01-01 |
| A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication (NCT00256997) | Janssen-Ortho Inc., Canada | 2006-01-01 |
| A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES) (NCT00173069) | National Taiwan University Hospital | 2006-01-01 |
| Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia (NCT00265551) | Wyeth is now a wholly owned subsidiary of Pfizer | 2006-01-01 |
| Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms (NCT00757978) | Hospital de Clinicas de Porto Alegre | 2006-01-01 |
| High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms (NCT00403546) | Donald C. Goff, MD | 2006-01-01 |
| A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder (NCT00796081) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2006-01-01 |
| Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome (NCT00288366) | Northwestern University | 2006-01-01 |
| The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia (NCT00495352) | Yu-Li Hospital | 2006-01-01 |
| Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia (NCT01726335) | Janssen-Cilag Ltd. | 2006-01-01 |
| A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine (NCT00791622) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2006-01-01 |
| Bifeprunox Extension to Extension Study in Patients With Schizophrenia (NCT00861497) | H. Lundbeck A/S | 2006-01-01 |
| Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia (NCT00328367) | Seoul National University Hospital | 2005-12-01 |
| 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777) (NCT00265343) | Organon and Co | 2005-12-01 |
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole (NCT00351936) | North Suffolk Mental Health Association | 2005-12-01 |
| Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis (NCT00320671) | Northwell Health | 2005-12-01 |
| Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia (NCT01576640) | Massachusetts General Hospital | 2005-12-01 |
| A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients (NCT00300846) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2005-12-01 |
| Risperdal Consta and Health Care Utilization in Patients With Schizophrenia (NCT00313391) | Emory University | 2005-12-01 |
| Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia (NCT00254202) | Vanda Pharmaceuticals | 2005-11-18 |
| An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia (NCT00823199) | Bronx Psychiatric Center | 2005-11-01 |
| Effects of RG1068 (Secretin) on Information Processing in Schizophrenia (NCT00235274) | Indiana University | 2005-11-01 |
| Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia (NCT00148590) | M. Schaefer, MD | 2005-11-01 |
| Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode (NCT00216671) | Janssen Pharmaceutica N.V., Belgium | 2005-11-01 |
| A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia (NCT00250575) | Novartis | 2005-11-01 |
| Treatment Effects From Aerobic Endurance Training and Maximal Strength Training in Patients Suffering From Schizophrenia (NCT00286299) | Norwegian University of Science and Technology | 2005-10-01 |
| Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis (NCT02305823) | Fundación Marques de Valdecilla | 2005-10-01 |
| β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS (NCT00528359) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2005-10-01 |
| Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids (NCT00211562) | Augusta University | 2005-10-01 |
| Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up (NCT02534363) | Fundación Marques de Valdecilla | 2005-10-01 |
| The Use of Skills Training to Augment Compensated Work Therapy (CWT)/VI for Veterans With SMI (NCT00272168) | VA Office of Research and Development | 2005-10-01 |
| Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect (NCT00534222) | AstraZeneca | 2005-09-01 |
| A Safety and Efficacy Study of Bacopa Monnieri and Nardostachys Jatamansi to Treat Schizophrenia (NCT00483964) | Q.Mundewadi Ayurvedic Research & Charitable Trust | 2005-09-01 |
| Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia (NCT00148083) | University of Illinois at Chicago | 2005-09-01 |
| Analysis of Genomic DNA Alterations in Familial Schizophrenia (NCT00166738) | National Taiwan University Hospital | 2005-09-01 |
| Risperidone LA Heathcare Resource Study (NCT00272597) | University of British Columbia | 2005-09-01 |
| Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation (NCT00167310) | University of Pittsburgh | 2005-09-01 |
| Staccato Loxapine Single Dose PK (NCT00444028) | Alexza Pharmaceuticals, Inc. | 2005-09-01 |
| SB-773812 Administered In Adults With Schizophrenia (NCT00259870) | GlaxoSmithKline | 2005-09-01 |
| Galantamine for Cognitive Deficits in Schizophrenia (NCT00463879) | Yale University | 2005-09-01 |
| Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia (NCT00216281) | Indiana University | 2005-09-01 |
| Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder (NCT00130923) | Dartmouth-Hitchcock Medical Center | 2005-09-01 |
| Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785) (NCT00156065) | Organon and Co | 2005-09-01 |
| Measuring Time Windows in Patients With Schizophrenia and Healthy Controls (NCT00350805) | University Hospital, Strasbourg, France | 2005-09-01 |
| Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia (NCT01213524) | Brown University | 2005-09-01 |
| Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia (NCT00255515) | AstraZeneca | 2005-09-01 |
| Bifeprunox in the Treatment of Schizophrenia (NCT00193687) | Solvay Pharmaceuticals | 2005-09-01 |
| A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients. (NCT00843687) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2005-09-01 |
| Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia (NCT00423943) | University of California, Los Angeles | 2005-09-01 |
| Bexarotene Treatment in Schizophrenia (NCT00141947) | Beersheva Mental Health Center | 2005-09-01 |
| Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo (NCT00149292) | Denovo Biopharma LLC | 2005-08-23 |
| The Quality of Life of Patients With Severe Illnesses (NCT00173329) | National Taiwan University Hospital | 2005-08-01 |
| Side Effects of Newer Antipsychotics in Older Adults (NCT00245206) | Veterans Medical Research Foundation | 2005-08-01 |
| Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia (NCT00139906) | Solvay Pharmaceuticals | 2005-08-01 |
| Effects of Atomoxetine on Cognitive Function in Schizophrenia (NCT00420498) | Yale University | 2005-08-01 |
| A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone (NCT00838669) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2005-08-01 |
| Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study (NCT00129441) | University of Pittsburgh | 2005-08-01 |
| Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone (NCT00361166) | ACADIA Pharmaceuticals Inc. | 2005-08-01 |
| An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia (NCT00269919) | Janssen Korea, Ltd., Korea | 2005-08-01 |
| Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine (NCT00312598) | University of North Carolina, Chapel Hill | 2005-08-01 |
| Recovery Group Pilot (NCT00522613) | Kaiser Permanente | 2005-07-01 |
| A First In Human Study Of PF-00184562 In Healthy Volunteers (NCT00150215) | Pfizer | 2005-07-01 |
| Cognitive Remediation in Supported Employment at Human Service Center (HSC) (NCT00138021) | Human Service Center, Illinois | 2005-07-01 |
| SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia (NCT00364429) | GlaxoSmithKline | 2005-07-01 |
| Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED) (NCT00156104) | Organon and Co | 2005-07-01 |
| AIMHI NT Relapse Prevention Trial (NCT00192582) | Menzies School of Health Research | 2005-07-01 |
| A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate (NCT01110317) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2005-07-01 |
| 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772) (NCT00174265) | Organon and Co | 2005-07-01 |
| A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (NCT00216528) | Janssen Korea, Ltd., Korea | 2005-07-01 |
| SPECT Study With SB-773812 In Schizophrenic Patients (NCT00269035) | GlaxoSmithKline | 2005-06-21 |
| A Switch Study of BMS-337039 in Schizophrenic Out-patients (NCT00232687) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2005-06-01 |
| Cognitive Behavioral Social Skills Training for Improving Social Functioning in People With Schizophrenia (NCT00338975) | Veterans Medical Research Foundation | 2005-06-01 |
| A Study of Strategies to Improve Schizophrenia Treatment (NCT00156637) | US Department of Veterans Affairs | 2005-06-01 |
| Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia (NCT00560937) | Durham VA Medical Center | 2005-06-01 |
| A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox Capsule (NCT01053429) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2005-06-01 |
| Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder (NCT00113594) | Eli Lilly and Company | 2005-06-01 |
| Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients (NCT00254787) | AstraZeneca | 2005-06-01 |
| PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders (NCT00399334) | Janssen-Cilag, S.A. | 2005-06-01 |
| The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes (NCT01832766) | University of Colorado, Denver | 2005-06-01 |
| ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health Registry (NCT00264069) | Janssen-Cilag, S.A. | 2005-06-01 |
| A Brief Community Linkage Intervention for Dually Diagnosed Individuals (NCT00137267) | US Department of Veterans Affairs | 2005-06-01 |
| SOLIACS: Solian Solution in the Acute Setting (NCT00245674) | Sanofi | 2005-06-01 |
| A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia (NCT00119756) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2005-06-01 |
| Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933) (NCT00156117) | Organon and Co | 2005-05-12 |
| Bifeprunox in the Treatment of Schizophrenia (NCT00193713) | Solvay Pharmaceuticals | 2005-05-01 |
| Schizophrenia and Genetic Counseling (NCT00111202) | Sarah Lawrence College | 2005-05-01 |
| Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics (NCT00458211) | Bronx Psychiatric Center | 2005-05-01 |
| Study of Amantadine for Weight Stabilization During Olanzapine Treatment (NCT00287352) | University of North Carolina, Chapel Hill | 2005-05-01 |
| Exercise and Diet Program for Schizophrenia Patients Who Are Taking Atypical Antipsychotic Medications (NCT01409590) | Sheba Medical Center | 2005-05-01 |
| A Study on Risk Mutations of Vulnerability Genes of Schizophrenia (NCT00155207) | National Taiwan University Hospital | 2005-05-01 |
| Amisulpride in Schizophrenic Acute Phase Patients (NCT00436371) | Sanofi | 2005-05-01 |
| Patient-reported Outcomes in the Treatment of Schizophrenia (NCT00230828) | Solvay Pharmaceuticals | 2005-05-01 |
| Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia (NCT00231894) | Nathan Kline Institute for Psychiatric Research | 2005-05-01 |
| Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia? (NCT00206986) | Birte Glenthoj | 2005-05-01 |
| To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox (NCT00141479) | Solvay Pharmaceuticals | 2005-05-01 |